Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Study of Standard Chemotherapy Alone or Combined with Atezolizumab for Patients with Stage III Colon Cancer
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAR9052
U.S. Govt. ID: NCT02912559
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study evaluates whether the addition of immune therapy to usual FOLFOX chemotherapy in patients with deficient DNA mismatch repair stage III colon cancer can improve your outcome compared to FOLFOX alone. The immune therapy drug, atezolizumab, may allow your body's immune system to more effectively kill cancer cells in your body. One of the purposes of this study is to determine if giving atezolizumab and the chemotherapy FOLFOX decreases the risk of colon cancer recurrence to a greater degree than does FOLFOX chemotherapy alone.
This study is closed
Investigator
Yoanna Pumpalova, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have stage III colon adenocarcinoma? Yes No
Have you had complete resection of your tumor? Yes No
Have you had no prior medical therapies? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE